Aoife Brennan
Known title: President and CEOCIK: 0001714563
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Kyntra Bio Names Andrew Singer to Board. Kyntra Bio has added Andrew E. Singer, MBA, to its board of directors. The move expands the company’s leadership team and could bring new expertise to its strategic planning. The appointment follows the company’s ongoing efforts to strengthen governance and support its growth initiatives. Investors may view the change as a sign of continued focus on development and operational improvement.
Transaction History
| CLYM | ▼ Sell | Open Market | 30,902 | $407K | 6/29/2026 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 68,750 | — | 6/27/2026 | View on chart |
| CLYM | ▼ Sell | Open Market | 20,618 | $25K | 6/30/2025 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 68,750 | — | 6/27/2025 | View on chart |
| KYNB | ▼ Sell | Open Market | 1,994 | $33K | 6/9/2023 | View on chart |
| KYNB | ▼ Sell | Open Market | 2,739 | $48K | 6/9/2023 | View on chart |
| KYNB | ▲ Buy | Grant | 8,289 | $0 | 6/7/2023 | View on chart |
| KYNB | ▲ Buy | Grant | 15,777 | $0 | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets
Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets. Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.